Sullivan & Cromwell has advised Japan's Sumitomo Pharma and its subsidiary Sumitovant on the $1.7 billion purchase of the remaining shares of Swiss pharmaceutical company Myovant Sciences, which was represented by Skadden, Arps, Slate, Meagher & Flom.

Sumitomo Pharma earlier owned 52 percent of Myovant via Sumitovant. The deal provides Sumitomo access to Myovant's clinical assets being developed for preventing pregnancy and treating infertility in women, in addition to the company's FDA-approved drugs for prostate cancer and managing menstrual bleeding, Reuters reported.

The S&C team was led by partners Alison Ressler in Los Angeles, Keiji Hatano in Tokyo, Matthew Goodman, David Spitzer, Marc Trevino, Tiffany Wooley and Matthew Schwartz in New York, Nader Mousavi in Palo Alto and Juan Rodriguez in London.

Meanwhile, the Skadden team was led by partners Thomas Greenberg and Stephen Arcano.